A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis
Peter Foley, Sinead Garrett, Lasse Ryttig
Current Medical Research and Opinion | TAYLOR & FRANCIS LTD | Published : 2018
P.F. has disclosed grant and personal fees from AbbVie, Amgen, Celgene, LEO, Lilly, Janssen, Novartis, Merck, Valeant, Galderma, Roche, and Sanofi. P.F. has also acted as an investigator in clinical trials for AbbVie, Merck, Valeant, UCB, BMS, Galderma, Gentech, GSK, Roche, Sanofi, Amgen, Celgene, LEO, Lilly, Janssen, and Boehringer Ingelheim. P.F. has received personal fees from Sun Pharma, UCB, and GSK. S.G. reports being contracted to deliver health economics services for publications from the Pharmaceutical Benefits Advisory Committee. L.R. is an employee of LEO Pharma. Peer reviewers on this manuscript have received an honorarium from CMRO for their review work. Two peer-reviewers have disclosed considerable support from Leo and from other companies that make products for psoriasis, and funding support from Johnson and Johnson, respectively.